XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.20.2

Stock-Based Compensation Expense (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock Based Compensation Expense Recognized in Accompanying Condensed Consolidated Statements of Operations | Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 was as follows (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
RSUs and options |  | $ | 1,225 |  |  | $ | 1,534 |  |  | $ | 4,413 |  |  | $ | 4,931 |
Employee stock purchase plan |  |  | 69 |  |  |  | 106 |  |  |  | 194 |  |  |  | 381 |
Total stock compensation expense |  | $ | 1,294 |  |  | $ | 1,640 |  |  | $ | 4,607 |  |  | $ | 5,312 |
Schedule of Employee Awards and Non-employee Director Award Plan Activity | During 2020, the Company granted the following awards:
|  | Three Months Ended |  |  | Three Months Ended |  |  | Three Months Ended |  |  | Nine Months Ended |
|  | March 31, 2020 |  |  | June 30, 2020 |  |  | September 30, 2020 |  |  | September 30, 2020 |
Employee awards: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Market RSUs |  |  | — |  |  |  | — |  |  |  | 1,571,000 |  | (7) |  | 1,571,000 |
RSUs |  |  | 230,000 |  | (1) |  | 2,109,228 |  | (2) |  | 1,776,250 |  | (8) |  | 4,115,478 |
Options |  |  | 78,500 |  | (3) |  | 117,900 |  | (4) |  | — |  |  |  | 196,400 |
Non-employee director awards: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
RSUs |  |  | 42,067 |  | (5) |  | 772,685 |  | (6) |  | — |  |  |  | 814,752 |
Total awards: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Market RSUs |  |  | — |  |  |  | — |  |  |  | 1,571,000 |  |  |  | 1,571,000 |
RSUs |  |  | 272,067 |  |  |  | 2,881,913 |  |  |  | 1,776,250 |  |  |  | 4,930,230 |
Options |  |  | 78,500 |  |  |  | 117,900 |  |  |  | — |  |  |  | 196,400 |
(1) | RSUs had a weighted average grant date fair value of $1.25 per share and a primary vesting period of four years.
(2) | RSUs had a weighted average grant date fair value of $1.34 per share and a primary vesting period of four years.
(3) | Options had a weighted average exercise price of $1.25 per share and vest over a four year period. The weighted average grant date fair value was $0.93 per share, as determined using a Black-Scholes option pricing model, with the following key assumptions: risk-free interest rate of 0.79%; expected life of approximately 5.67 years; volatility of 93.83%, and dividend yield of zero.
(4) | Options had a weighted average exercise price of $1.34 per share and vest over a four year period. The weighted average grant date fair value was $0.99 per share, as determined using a Black-Scholes option pricing model, with the following key assumptions: risk-free interest rate of 0.39%; expected life of approximately 5.67 years; volatility of 93.83%, and dividend yield of zero.
(5) | RSUs had a weighted average grant date fair value of $1.17 per share and vested immediately upon grant, but the underlying shares of common stock will not be delivered until there is a separation of service, such as resignation, retirement or death.
(6) | RSUs had a weighted average grant date fair value of $1.34 per share and vested immediately upon grant, but the underlying shares of common stock will not be delivered until there is a separation of service, such as resignation, retirement or death.
(7) | Market RSUs had a grant date fair value of $3.77 per share and will vest on May 22, 2023 provided that the closing price of the Company’s common stock on such vesting date is not less than the closing price on August 27, 2020. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from August 27, 2020 until May 22, 2023 related to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
(8) | RSUs had a weighted average grant date fair value of $1.70 per share and a primary vesting period of four years.

X
- Definition Schedule of share based compensation employee stock purchase plan and non employee director stock award plan activity. + References No definition available. + Details
Name: | mnkd_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock
Namespace Prefix: | mnkd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration